All In Biotech

Drug Trial Radar · NCT00975195

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

Last checked: Nov 19, 2026Latest source record: Feb 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,488 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,488

Actual

Start

Feb 2009

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled corticosteroid on top of two potent long-acting bronchodilators. The study also aims to identify the type of patients who are likely to benefit from inhaled corticosteroid maintenance therapy.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • tiotropium inhalationDrug

  • salmeterol xinafoateDrug

  • fluticasone propionateDrug

  • placebo matched for fluticasone propionateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Moderate or Severe On-treatment COPD ExacerbationTime frame: During randomised treatment, up to 488 days

Locations

222 sites in 23 countries. Site status is shown where the registry gives one.

  • 352.2046.61006 Boehringer Ingelheim Investigational Site

    Concord, New South Wales, Australia

  • 352.2046.61001 Boehringer Ingelheim Investigational Site

    Glebe, New South Wales, Australia

  • 352.2046.61002 Boehringer Ingelheim Investigational Site

    Westmead, New South Wales, Australia

  • 352.2046.61004 Boehringer Ingelheim Investigational Site

    Daw Park, South Australia, Australia

  • 352.2046.61003 Boehringer Ingelheim Investigational Site

    Toorak Gardens, South Australia, Australia

  • 352.2046.61005 Boehringer Ingelheim Investigational Site

    Woodville, South Australia, Australia

  • 352.2046.32002 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 352.2046.32016 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 352.2046.32015 Boehringer Ingelheim Investigational Site

    Eupen, Belgium

  • 352.2046.32017 Boehringer Ingelheim Investigational Site

    Gilly, Belgium

  • 352.2046.32014 Boehringer Ingelheim Investigational Site

    Herentals, Belgium

  • 352.2046.32006 Boehringer Ingelheim Investigational Site

    Jambes, Belgium

  • 352.2046.32008 Boehringer Ingelheim Investigational Site

    Lebbeke, Belgium

  • 352.2046.32001 Boehringer Ingelheim Investigational Site

    Leuven, Belgium

  • 352.2046.32004 Boehringer Ingelheim Investigational Site

    Middelheim, Belgium

  • 352.2046.32010 Boehringer Ingelheim Investigational Site

    Montigny-le-Tilleul, Belgium

  • 352.2046.32013 Boehringer Ingelheim Investigational Site

    Turnhout, Belgium

  • 352.2046.55002 Boehringer Ingelheim Investigational Site

    Goiânia, Brazil

  • 352.2046.55005 Boehringer Ingelheim Investigational Site

    Goiânia, Brazil

  • 352.2046.55001 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 352.2046.55006 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 352.2046.55003 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 352.2046.35905 Boehringer Ingelheim Investigational Site

    Burgas, Bulgaria

  • 352.2046.35902 Boehringer Ingelheim Investigational Site

    Rousse, Bulgaria

  • 352.2046.35904 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 352.2046.35906 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 352.2046.35907 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 352.2046.35908 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 352.2046.35903 Boehringer Ingelheim Investigational Site

    Stara Zagora, Bulgaria

  • 352.2046.35909 Boehringer Ingelheim Investigational Site

    Veliko Tarnovo, Bulgaria

  • 352.2046.86002 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 352.2046.86003 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 352.2046.86006 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 352.2046.86008 Boehringer Ingelheim Investigational Site

    Chongqing, China

  • 352.2046.86001 Boehringer Ingelheim Investigational Site

    Guangzhou, China

  • 352.2046.86004 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 352.2046.86005 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 352.2046.86007 Boehringer Ingelheim Investigational Site

    Wuhan, China

  • 352.2046.45001 Boehringer Ingelheim Investigational Site

    Aarhus C, Denmark

  • 352.2046.45003 Boehringer Ingelheim Investigational Site

    København NV, Denmark

Showing 40 of 222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.